pubmed.ncbi.nlm.nih.gov

Transforming obesity: The advancement of multi-receptor drugs - PubMed

  • ️Fri Jul 25 2025

Review

. 2024 Jul 25;187(15):3829-3853.

doi: 10.1016/j.cell.2024.06.003.

Affiliations

Review

Transforming obesity: The advancement of multi-receptor drugs

Christine M Kusminski et al. Cell. 2024.

Abstract

For more than a century, physicians have searched for ways to pharmacologically reduce excess body fat. The tide has finally turned with recent advances in biochemically engineered agonists for the receptor of glucagon-like peptide-1 (GLP-1) and their use in GLP-1-based polyagonists. These polyagonists reduce body weight through complementary pharmacology by incorporating the receptors for glucagon and/or the glucose-dependent insulinotropic polypeptide (GIP). In their most advanced forms, gut-hormone polyagonists achieve an unprecedented weight reduction of up to ∼20%-30%, offering a pharmacological alternative to bariatric surgery. Along with favorable effects on glycemia, fatty liver, and kidney disease, they also offer beneficial effects on the cardiovascular system and adipose tissue. These new interventions, therefore, hold great promise for the future of anti-obesity medications.

Copyright © 2024 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.M.K. and P.E.S. have sponsored research agreements with Eli Lilly. M.H.T. was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. He received funding for his research projects by Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He consulted twice for Boehringer Ingelheim Pharma GmbH & Co. KG (2020 and 2021) and delivered a scientific lecture for Sanofi-Aventis Deutschland GmbH (2020). As CEO and CSO of Helmholtz Munich, he is co-responsible for numerous collaborations of the employees with a multitude of companies and institutions worldwide. In this capacity, he discusses potential projects with and has signed/signs contracts for the Helmholtz institute(s) related to research collaborations worldwide, including but not limited to pharmaceutical corporations like Boehringer Ingelheim, Novo Nordisk, Roche Diagnostics, Arbormed, Eli Lilly, SCG Cell Therapy, and others. As the CEO and CSO of Helmholtz Munich, he was/is further overall responsible for commercial technology transfer activities. M.H.T. confirms that, to the best of his knowledge, none of the above funding sources or collaborations were involved in or had an influence on the preparation of this manuscript. M.H.T. is a former member of the scientific advisory board of ERX, which is developing celastrol, but has no current competing interests. R.D.D. is the co-inventor of multiple patents pertaining to this field that are owned by Indiana University. He was co-founder of Marcadia Biotech and a former employee at Eli Lilly Research labs and Novo Nordisk, advancing drug candidates associated with the subject of this review. T.D.M. receives research funding from Novo Nordisk; however, these funds are unrelated to the work described here. T.D.M. further received speaking fees within the past 3 years from Novo Nordisk, Eli Lilly, AstraZeneca, Merck, Berlin Chemie AG, and Mercodia.

Similar articles

References

    1. Dale CE, Fatemifar G, Palmer TM, White J, Prieto-Merino D, Zabaneh D, Engmann JEL, Shah T, Wong A, Warren HR, et al. (2017). Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus: A Mendelian Randomization Analysis. Circulation 135, 2373–2388. 10.1161/CIRCULATIONAHA.116.026560. - DOI - PMC - PubMed
    1. Islami F, Goding Sauer A, Gapstur SM, and Jemal A (2019). Proportion of Cancer Cases Attributable to Excess Body Weight by US State, 2011-2015. JAMA Oncol 5, 384–392. 10.1001/jamaoncol.2018.5639. - DOI - PMC - PubMed
    1. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, et al. (2010). Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363, 2211–2219. 10.1056/NEJMoa1000367. - DOI - PMC - PubMed
    1. Sawadogo W, Tsegaye M, Gizaw A, and Adera T (2022). Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. BMJ Nutr Prev Health 5, 10–18. 10.1136/bmjnph-2021-000375. - DOI - PMC - PubMed
    1. Collaboration, N.C.D.R.F. (2016). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 387, 1377–1396. 10.1016/S0140-6736(16)30054-X. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources